Immune responses to vaccines involving a combined antigen-nanoparticle mixture and nanoparticle-encapsulated antigen formulation.
暂无分享,去创建一个
Guanghui Ma | G. Ma | Lianyan Wang | Lianyan Wang | Shaohui Qiu | Jilei Jia | Weifeng Zhang | Qi Liu | Tingyuan Yang | Yuan Liu | Weifeng Zhang | Xiaoming Chen | Tingyuan Yang | Qi Liu | Jilei Jia | Yuan Liu | Xiaoming Chen | S. Qiu
[1] P. Marrack,et al. Towards an understanding of the adjuvant action of aluminium , 2009, Nature Reviews Immunology.
[2] J. Kreuter,et al. New adjuvants on a polymethylmethacrylate base , 1976, Infection and immunity.
[3] Lihua Wu,et al. Paclitaxel acts as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice. , 2010, Vaccine.
[4] Christophe Benoist,et al. Antigen persistence is required throughout the expansion phase of a CD4+ T cell response , 2005, The Journal of experimental medicine.
[5] H. Alpár,et al. Potential use of nanoparticles for transcutaneous vaccine delivery: effect of particle size and charge. , 2004, International journal of pharmaceutics.
[6] E. Wherry,et al. Vaccines: Effector and memory T-cell differentiation: implications for vaccine development , 2002, Nature Reviews Immunology.
[7] D. Irvine,et al. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction , 2012, Proceedings of the National Academy of Sciences.
[8] Joel A. Cohen,et al. Acetalated dextran is a chemically and biologically tunable material for particulate immunotherapy , 2009, Proceedings of the National Academy of Sciences.
[9] Sven Frokjaer,et al. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. , 2005, International journal of pharmaceutics.
[10] Martin F. Bachmann,et al. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns , 2010, Nature Reviews Immunology.
[11] Yvonne Perrie,et al. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[12] D. Turner,et al. Duration of Antigen Availability Influences the Expansion and Memory Differentiation of T Cells , 2011, The Journal of Immunology.
[13] N. Van Rooijen,et al. Prolonged Antigen Presentation Is Required for Optimal CD8+ T Cell Responses against Malaria Liver Stage Parasites , 2010, PLoS pathogens.
[14] W. Oyen,et al. Route of Administration Modulates the Induction of Dendritic Cell Vaccine–Induced Antigen-Specific T Cells in Advanced Melanoma Patients , 2011, Clinical Cancer Research.
[15] Bali Pulendran,et al. Immunological mechanisms of vaccination , 2011, Nature Immunology.
[16] O. Lantz,et al. Antigen Persistence Is Required for Dendritic Cell Licensing and CD8+ T Cell Cross-Priming1 , 2008, The Journal of Immunology.
[17] Rino Rappuoli,et al. Vaccine manufacturing: challenges and solutions , 2006, Nature Biotechnology.
[18] J. Buer,et al. The use of calcium phosphate nanoparticles encapsulating Toll-like receptor ligands and the antigen hemagglutinin to induce dendritic cell maturation and T cell activation. , 2010, Biomaterials.
[19] Zhengrong Cui,et al. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses , 2010, Expert review of vaccines.
[20] V. Kanchan,et al. Memory antibody response from antigen loaded polymer particles and the effect of antigen release kinetics. , 2009, Biomaterials.
[21] T. Kündig,et al. Surface coating of PLGA microparticles with protamine enhances their immunological performance through facilitated phagocytosis. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[22] J. Schlom,et al. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. , 2007, Vaccine.
[23] R. R. Anderson,et al. A Novel Laser Vaccine Adjuvant Increases the Motility of Antigen Presenting Cells , 2010, PloS one.
[24] Eric Stern,et al. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. , 2012, Biomaterials.
[25] T. Rades,et al. Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[26] S. Tangye,et al. Follicular helper T cell differentiation requires continuous antigen presentation that is independent of unique B cell signaling. , 2010, Immunity.
[27] Polly Matzinger,et al. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses , 2004, Nature Reviews Immunology.
[28] Dan Peer,et al. Nanoparticle hydrophobicity dictates immune response. , 2012, Journal of the American Chemical Society.
[29] C. Vinuesa,et al. The elusive identity of T follicular helper cells. , 2010, Trends in immunology.
[30] G. Ma,et al. Comparison of PLA Microparticles and Alum as Adjuvants for H5N1 Influenza Split Vaccine: Adjuvanticity Evaluation and Preliminary Action Mode Analysis , 2013, Pharmaceutical Research.
[31] D. Irvine,et al. Particulate vaccines: on the quest for optimal delivery and immune response. , 2011, Drug discovery today.
[32] T. Kündig,et al. Antigen kinetics determines immune reactivity , 2008, Proceedings of the National Academy of Sciences.
[33] L. Malherbe,et al. Regulation of CD4 T‐cell receptor diversity by vaccine adjuvants , 2010, Immunology.
[34] R. Melamed,et al. Sustained antigen presentation can promote an immunogenic T cell response, like dendritic cell activation , 2007, Proceedings of the National Academy of Sciences.
[35] Derek T. O'Hagan,et al. Recent Advances in Vaccine Adjuvants , 2002, Pharmaceutical Research.